[Abstract Only] Randomized Trial: Overall Survival with a (CDK) 4/6 inhibitor plus Endocrine Therapy in Breast Cancer

19 Jun, 2019 | 07:48h | UTC

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: MONALEESA-7 Shows Overall Survival Benefit for Ribociclib/Endocrine Therapy – The ASCO Post (free)

 

Join our WhatsApp group

Free Updates in All Specialties!

A daily update on the latest medical news, practice-changing trials and guidelines

Stay Updated in Your Specialty
No spam, just news
Unsubscribe with one click

 

Daily

 

Weekly or Less Often 
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •